GLASGOW, Scotland–(BUSINESS WIRE)–Dxcover, a global leader in innovative AI-enabled technologies, today announced the availability of its UKCA1-approved, blood-based brain cancer early detection test in the UK.
The new validated test has demonstrated a 99.3% negative predictive value2 (NPV), enabling GPs to provide earlier reassurance to symptomatic patients, inform referral into imaging, and reach an earlier diagnosis. UK-based GPs and private specialists are invited to register their interest to enable access to the test and integrate it into existing referral workflows for the triage of symptomatic patients into imaging or specialist assessment.
“To date, blood-based detection of brain malignancies has been out of reach, with too many technical challenges for other technologies,” said Matthew J. Baker, CEO and co-Founder of Dxcover. “But now a minimally invasive clinical test can help improve outcomes for patients and enable treatment developments to move faster in this space.”
Brain and central nervous system (CNS) tumours are relatively rare, with 300,000 new cases diagnosed globally each year, usually at a very serious stage with few treatment options. Five-year survival is approximately 33%, yet evidence indicates that even a one-month improvement in time to diagnosis could reduce mortality by 18–28%3.
Continued pressure on diagnostic imaging capacity means many patients presenting with neurological symptoms experience delays between initial consultation, scan referral, imaging, and definitive diagnosis. Dxcover’s blood-based test is designed to support referral decisions and prioritisation on suspected tumour pathways while patients await CT or MRI scans.
The Dxcover Liquid Biopsy Platform can deliver results in under 24 hours. For patients with a positive result, the test supports evidence-based escalation, helping to prioritise referrals, justify urgent imaging requests, and align patients more quickly to the appropriate secondary care pathway.
About Dxcover
Dxcover is changing how early, how accurately, and how efficiently cancer can be detected. The company’s platform integrates infrared spectroscopy with proprietary algorithms and other clinical information to support earlier and more actionable clinical insights from a small amount of blood, yielding results in hours instead of weeks. AI-powered insight, delivered at light speed.
Further Information: https://www.dxcover.com.
|
1United Kingdom Conformity Assessment | 2Brennan, et al. ESMO 2026 | 3Gray, et al. medRxiv 2025 |
Contacts
Media Contact: [email protected]
